Patents by Inventor Barbara Slusher

Barbara Slusher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210000798
    Abstract: Methods for treating one or more diseases associated with neutral sphingomyelinase 2 (nSMase2) in a subject in need of treatment thereof, the method comprising administering to the subject a therapeutically effective amount of 2,6-dimethoxy-4-(5-phenyl-4-thiophen-2-yl-1H-imidazol-2-yl)-phenol (DPTIP) or a pharmaceutically acceptable salt thereof, are disclosed.
    Type: Application
    Filed: March 1, 2019
    Publication date: January 7, 2021
    Inventors: Barbara Slusher, Camilo Rojas, Ajit G. Thomas, Norman Haughey
  • Publication number: 20210000833
    Abstract: Methods for treating a Human Immunodeficiency Virus (HIV) infection comprising administering to a subject in need of treatment thereof an effective amount of a small molecule nSMase2 inhibitor.
    Type: Application
    Filed: March 1, 2019
    Publication date: January 7, 2021
    Inventors: Norman Haughey, Barbara Slusher, Camilo Rojas
  • Publication number: 20200399298
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA
    Type: Application
    Filed: January 24, 2020
    Publication date: December 24, 2020
    Inventors: BARBARA SLUSHER, RANA RAIS, MARCELA KRECMEROVA, TOMAS TICHY, PAVEL MAJER, ANDREJ JANCARIK
  • Patent number: 10849915
    Abstract: Methods and compounds are disclosed for treating inflammatory bowel disease (IBD) by using Prostate Specific Membrane Antigen (PSMA) inhibitors.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: December 1, 2020
    Assignee: The Johns Hopkins University
    Inventors: Barbara Slusher, Rana Rais, Xuhang Li
  • Patent number: 10842763
    Abstract: The disclosure provides methods of treating cancer in a subject or preventing a relapse or reducing the incidence of relapse of cancer in a subject in remission, comprising administering to the subject: (a) a therapeutically effective amount of an immunotherapeutic agent, e.g., an immune checkpoint blockade therapy, an adoptive cellular therapy, a marrow-infiltrating lymphocytes, an adenosine A2aR inhibitor, or an antibody; and (b) a compound having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: November 24, 2020
    Assignees: The Johns Hopkins University, Ústav organické chemie a biochemie AV {hacek over (C)}r, v.v.i.
    Inventors: Barbara Slusher, Jonathan Powell, Lukas Tenora, Pavel Majer, Andrei Jancarik, Robert Leone, Judson Englert
  • Publication number: 20200289404
    Abstract: Methods for buccally, sublingually, or intranasally administering a prodrug of propofol to a subject in need of treatment thereof in an amount sufficient to deliver a therapeutically effective amount of propofol to the subject are disclosed.
    Type: Application
    Filed: May 25, 2017
    Publication date: September 17, 2020
    Inventors: Barbara Slusher, Rana Rais, James Vornov
  • Patent number: 10738066
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: August 11, 2020
    Assignees: The Johns Hopkins University, Ústav organické chemie a biochemie AV {hacek over (C)}R, v.v.i.
    Inventors: Barbara Slusher, Rana Rais, Lukas Tenora, Pavel Majer, Andrej Jancarik
  • Publication number: 20200230111
    Abstract: Prodrugs of glutamine analogs, such as prodrugs of acivicin, are disclosed.
    Type: Application
    Filed: February 1, 2018
    Publication date: July 23, 2020
    Inventors: Barbara Slusher, Pavel Majer, Lukas Tenora, Katerina Novotna, Peter Michael Hudlicky
  • Publication number: 20200190089
    Abstract: Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) and their use for treating neurodegenerative diseases, such as, neurodegenerative diseases associated with high levels of ceramide, including, but not limited to Alzheimer's disease (AD), HIV-associated neurocognitive disorder (HAND), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS), and, in other aspects, for treating cancer, are provided.
    Type: Application
    Filed: January 5, 2018
    Publication date: June 18, 2020
    Inventors: Barbara Slusher, Camilo Rojas, Ajit G. Thomas, Radim Nencka, Michal Sala, Hubert Hrebabecky
  • Publication number: 20200069706
    Abstract: The use of a class of prodrugs of 2-PMPA that alter tissue distribution of 2-PMPA to non-prostate tissues is disclosed. The presently disclosed prodrugs preferentially distribute to healthy tissues including the kidney, lacrimal glands, and salivary glands, which represent sites of off-target binding and toxicity for PSMA-targeted prostate cancer imaging agents and therapies. Accordingly, the 2-PMPA prodrugs can be used to pretreat, bind to, and shield the kidney and salivary glands from PSMA-targeted cytotoxic or radiotherapy.
    Type: Application
    Filed: April 11, 2018
    Publication date: March 5, 2020
    Inventors: Barbara Slusher, Michael Nedelcovych, Rana Rais, Clemens Kratochwil
  • Patent number: 10568868
    Abstract: The disclosure provides methods of treating a condition, disease, or disorder in a subject that involves metabolically reprogrammed cells whose activation, function, growth, proliferation, or survival depends on increased activity of at least one metabolic pathway selected from the group consisting of glutamine metabolism, glycolysis, and fatty acid synthesis, comprising administering to the subject a compound having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: February 25, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Barbara Slusher, Jonathan Powell
  • Patent number: 10544176
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: January 28, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Barbara Slusher, Rana Rais, Marcela Krecmerova, Tomas Tichy, Pavel Majer, Andrej Jancarik
  • Publication number: 20190352255
    Abstract: Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.
    Type: Application
    Filed: November 20, 2017
    Publication date: November 21, 2019
    Inventors: Barbara Slusher, Rana Rais, Jan Vavra, Tomas Tichy, Pavel Majer, Andrej Jancarik, Lukas Tenora
  • Publication number: 20190315784
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.
    Type: Application
    Filed: June 27, 2019
    Publication date: October 17, 2019
    Inventors: Barbara Slusher, Rana Rais, Lukas Tenora, Pavel Majer, Andrej Jancarik
  • Publication number: 20190315783
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.
    Type: Application
    Filed: June 27, 2019
    Publication date: October 17, 2019
    Inventors: Barbara Slusher, Rana Rais, Lukas Tenora, Pavel Majer, Andrej Jancarik
  • Publication number: 20190216757
    Abstract: The disclosure provides methods of treating cancer in a subject or preventing a relapse or reducing the incidence of relapse of cancer in a subject in remission, comprising administering to the subject: (a) a therapeutically effective amount of an immunotherapeutic agent, e.g., an immune checkpoint blockade therapy, an adoptive cellular therapy, a marrow-infiltrating lymphocytes, an adenosine A2aR inhibitor, or an antibody; and (b) a compound having formula (1): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).
    Type: Application
    Filed: January 30, 2019
    Publication date: July 18, 2019
    Inventors: Barbara Slusher, Jonathan POWELL
  • Patent number: 10336778
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: July 2, 2019
    Assignees: The Johns Hopkins University, Ústav organické chemie a biochemie AV {hacek over (C)}R, v.v.i.
    Inventors: Barbara Slusher, Rana Rais, Lukas Tenora, Pavel Majer, Andrej Jancarik
  • Publication number: 20190076447
    Abstract: Methods and compounds are disclosed for treating inflammatory bowel disease (IBD) by using Prostate Specific Membrane Antigen (PSMA) inhibitors.
    Type: Application
    Filed: November 14, 2018
    Publication date: March 14, 2019
    Inventors: Barbara Slusher, Rana Rais, Xuhang Li
  • Patent number: 10172873
    Abstract: Methods and compounds are disclosed for treating inflammatory bowel disease (IBD) by using Prostate Specific Membrane Antigen (PSMA) inhibitors.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: January 8, 2019
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Barbara Slusher, Rana Rais, XUHANG Li
  • Publication number: 20180244705
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.
    Type: Application
    Filed: May 1, 2018
    Publication date: August 30, 2018
    Inventors: BARBARA SLUSHER, RANA RAIS, MARCELA KRECMEROVA, TOMAS TICHY, PAVEL MAJER, ANDREJ JANCARIK